Connect with us


Amgen goals to enter weight reduction drug market with a brand new strategy




The Amgen brand is displayed outdoors Amgen headquarters on Could 17, 2023 in Thousand Oaks, California.

Mario Tama | Getty Photographs


Amgen is taking a new approach because it tries to face out in a crowded subject of drugmakers racing to develop the following blockbuster weight loss drug.

The biotech firm is testing an injectable treatment that helps folks shed pounds in another way from the prevailing injections from Novo Nordisk and Eli Lilly, and different weight problems medicines in growth. Amgen’s therapy, referred to as MariTide, additionally seems to assist sufferers preserve weight off after they cease taking it.  


The drugmaker can be testing its drug to be taken as soon as a month and even much less often, which might provide extra comfort than the weekly medicines available on the market. 

It is too early to say how aggressive Amgen will probably be within the budding weight reduction drug house, which Novo Nordisk and Eli Lilly have to date dominated.


Some analysts count on the market could possibly be value $100 billion by the top of the last decade, probably leaving room for brand new rivals to enter. Goldman Sachs additionally projects that between 10 million and 70 million Individuals will probably be taking weight reduction medication by 2028.

The obtainable knowledge on Amgen’s injectable drug is promising, however it’s from a small, early-stage clinical trial. The Thousand Oaks, California-based firm is also creating an oral drugs and different therapies for weight problems, however has disclosed few particulars about them. 


Buyers and well being specialists will seemingly get a greater thought of Amgen’s prospects later this 12 months: The drugmaker expects to launch preliminary knowledge from an ongoing mid-stage trial on MariTide, together with section one knowledge on its weight problems tablet. 

It is also unclear whether or not Amgen’s therapies will probably be cheaper than the prevailing weight reduction medication, which value round $1,000 per 30 days.


Wegovy from Novo Nordisk and Zepbound from Eli Lilly lead a brand new class of weight problems therapies that has drawn unrelenting affected person demand — and investor curiosity — regardless of their hefty value tags and restricted insurance coverage protection. 

Eli Lilly and Novo Nordisk have additionally struggled to supply sufficient provide of their therapies, which might give different corporations an opportunity to win market share.  


How Amgen’s therapy is totally different

Amgen’s drug gives a new twist on weight reduction. 

Very similar to Wegovy and Zepbound, one a part of Amgen’s therapy prompts a intestine hormone receptor referred to as GLP-1 to assist regulate an individual’s urge for food. 


However whereas Zepbound prompts a second hormone receptor referred to as GIP, Amgen’s drug blocks it. Wegovy doesn’t goal GIP, which suppresses urge for food like GLP-1 however may additionally enhance how the physique breaks down sugar and fats.

Amgen’s choice to tamp down relatively than enhance GIP exercise relies on genetics analysis suggesting that blocking the receptor is linked to decrease fats mass and physique weight, firm executives have stated. 


Some authorised and experimental weight reduction medication

  • Wegovy from Novo Nordisk: Permitted weekly injection that prompts GLP-1
  • Zepbound from Eli Lilly: Permitted weekly injection that prompts GLP-1 and GIP
  • Saxenda from Novo Nordisk: Permitted weekly injection that prompts GLP-1
  • MariTide from Amgen: Experimental month-to-month injection that prompts GLP-1 and blocks GIP
  • Danuglipron from Pfizer: Experimental once-daily tablet that prompts GLP-1
  • VK2735 from Viking Therapeutics: Experimental weekly injection that prompts GLP-1 and GIP
  • Pemvidutide from Altimmune: Experimental weekly injection that prompts GLP-1 and one other intestine hormone referred to as glucagon
  • GSBR-1290 from Construction Therapeutics: Experimental weekly tablet that prompts GLP-1
  • Survodutide from Zealand Pharma, Boehringer Ingelheim: Experimental weekly injection that prompts GLP-1 and glucagon

That seems to contradict how Zepbound works. Eli Lilly’s strategy has confirmed profitable: The therapy helped sufferers with weight problems lose as much as 22.5% of their weight after 72 weeks in a late-stage trial.

However Amgen’s MartiTide additionally was efficient in a small, early-stage research. 


Sufferers given the very best dose of Amgen’s drug — 420 milligrams — each month misplaced 14.5% of their physique weight on common in simply 12 weeks, based on data from the phase one trial printed final month within the journal Nature Metabolism. 

There is a broader debate amongst researchers about why each approaches – blocking and activating GIP – are efficient at selling weight reduction. 


One theory is that repeatedly activating the GIP receptor, as Zepbound does, finally causes the physique to “self-regulate” itself and ensure there is not an excessive amount of GIP exercise, stated Dr. Caroline Apovian, a director of the Middle for Weight Administration and Wellness at Brigham and Girls’s Hospital.

That decreases GIP exercise general, which is believed to basically mimic what Amgen’s drug achieves when it blocks the GIP receptor. However Apovian cautioned that “none of that is confirmed” and extra knowledge is required.


The drug might end in longer-lasting weight reduction

Amgen’s therapy could also be higher at serving to folks preserve weight reduction than rivals, regardless that sufferers take it much less often, early-stage trial knowledge suggests.

Amgen’s research enrolled 110 sufferers with weight problems however not diabetes. Sufferers in a single group had been randomly assigned to obtain a single dose of the drug and had been adopted for 150 days, whereas a second group was given a dose each 4 weeks for 3 months. 


An weight problems affected person takes a injection of weight reduction medicine.

Joe Buglewicz | The Washington Publish | Getty Photographs


As soon as a month and even much less frequent dosing 

The frequency of Amgen’s drug additionally units it aside. These on Wegovy or Zepbound should take doses weekly, in contrast with the once-monthly MariTide. 

Amgen’s trial used month-to-month dosing partly as a result of sufferers noticed sustained weight reduction whether or not they had a single injection or a number of photographs of the corporate’s drug, based on the research authors. 


Amgen’s therapy can also keep within the physique for for much longer than present therapies like Wegovy and Zepbound as a result of it features a monoclonal antibody, the authors added. 

An injection pen of Zepbound, Eli Lilly’s weight reduction drug, is displayed in New York Metropolis, U.S., December 11, 2023. 


Brendan McDermid | Reuters

Amgen’s MariTide “has that benefit the place it is simply going to final rather a lot longer. Even should you give a excessive dose, you are still going to have drug publicity within the physique for a month or two months, in order that clearly reveals you need not take it each week,” William Blair & Firm analyst Matt Phipps advised CNBC.


Phipps stated folks sometimes do not wish to get injections typically, so some sufferers might favor a month-to-month shot like Amgen’s MariTide for a illness that can seemingly require power therapy. 

However he famous {that a} affected person’s alternative may additionally rely on whether or not the extent of weight reduction and uncomfortable side effects of Amgen’s drug find yourself being on par with these of the prevailing weekly injections. 


Amgen’s ongoing section two trial is exploring whether or not sufferers can take its drug even much less often than as soon as a month. 

Part two trial will carry extra readability

Amgen’s longer-term section two research on practically 600 sufferers will present extra readability on how aggressive MariTide will probably be in opposition to Wegovy and Zepbound. The corporate is exploring which dose power and schedule is finest for sufferers. It expects to launch preliminary trial outcomes later this 12 months. 


Some analysts have stated the section two trial might assist tackle a number of questions, together with how properly sufferers tolerate the therapy at totally different dose regimens.

The 52-week research is testing 11 totally different affected person teams at a wide range of dosing ranges and regimens. That features beginning some sufferers at a decrease dose of a drug and regularly rising it till they attain the next goal dose. 


That dose escalation might assist scale back uncomfortable side effects that some sufferers skilled after taking their first dose of MariTide within the section one trial, based on Phipps.

In that trial, the security and uncomfortable side effects of Amgen’s drug had been just like different GLP-1 medicines. Nausea and vomiting had been probably the most generally reported uncomfortable side effects, and sometimes lasted for about 72 hours. 


4 out of eight sufferers in a gaggle receiving the very best dose of the therapy withdrew earlier than getting a second shot as a result of delicate gastrointestinal points, based on the research. However no different sufferers stopped taking the drug as a result of antagonistic occasions throughout any of the totally different dosing teams, Amgen Chief Medical Officer Paul Burton stated throughout a convention earlier this month. 

“It is somewhat early to leap to the conclusion that the drug will not be tolerated by sufferers based mostly on this section one knowledge,” William Blair & Firm’s Phipps stated.


One other a part of Amgen’s section two trial may even look at weight reduction past 52 weeks, which can present a clearer image of how lengthy the drug is efficient.

Don’t miss these tales from CNBC PRO:

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *